Navigation Links
Accuray Incorporated to Report Second Quarter Fiscal Year 2008 Financial Results
Date:12/21/2007

SUNNYVALE, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its second quarter fiscal year 2008, ending December 29, 2007, on Wednesday, January 30, 2008 after the market closes.

A conference call to review the results will begin at 2:00 p.m. PST (5:00 p.m. EST) and will be hosted by Euan S. Thomson, Ph.D., president and chief executive officer and Robert E. McNamara, senior vice president and chief financial officer.

The conference call dial-in numbers are (866) 288-0541 (USA) or (913) 312-1268 (International), Access Code: 4129411. In addition, a dial-up replay of the conference call will be available beginning January 30, 2008 at 5:00 p.m. PST (8:00 p.m. EST) and ending on February 14, 2008. The replay telephone number is (888) 203-1112 (USA) or (719) 457-0820 (International), Access Code: 4129411.

A live webcast of the call will also be available from the Investor Relations section of the corporate Web site at http://www.accuray.com. A webcast replay can be accessed on the corporate Web site beginning Wednesday, January 30, 2008 at approximately 5:00 p.m. PST (8:00 p.m. EST). The replay will remain available until Accuray announces its results for the third quarter of fiscal 2008, ending March 31, 2008.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-Q for the quarterly period ended September 29, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward- looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
2. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
3. Accuray to Webcast Senior Management Presentations at Analyst Day Event
4. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
5. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007
6. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
7. Accuray Reports Record Revenue in First Quarter of Fiscal 2008
8. Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System
9. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
10. Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend
11. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... specializing in medical device compliance and commercialization, has just released a new ... , FDA is more adamant than ever about medical device, pharmaceutical, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The Garland ... a redesigned website. The new site – still located at http://www.garlandco.com ... and other industry users that Garland serves. , After an ambitious phase of ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
(Date:9/20/2017)... ... 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted pricing ... 40-Hour courses from now until November 30, 2017 to assist with the clean-up efforts ... to all businesses and government agencies – whether or not they will be directly ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story of ... life. This mouse sets out on a journey that will show that friends are ... creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology: